The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

BACKGROUND: The prognosis of patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC) is poor. There is no standard treatment available. Emerging evidence suggests a major role for antiangiogenic treatment modalities in EOC, in particular in combination with the metronomic applica...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichbaum, Michael, Mayer, Christine, Eickhoff, Regina, Bischofs, Esther, Gebauer, Gerhard, Fehm, Tanja, Lenz, Florian, Fricke, Hans-Christian, Solomayer, Erich, Fersis, Nikos, Schmidt, Marcus, Wallwiener, Markus, Schneeweiss, Andreas, Sohn, Christof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224456/
https://www.ncbi.nlm.nih.gov/pubmed/22014006
http://dx.doi.org/10.1186/1471-2407-11-453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224456/
https://www.ncbi.nlm.nih.gov/pubmed/22014006
http://dx.doi.org/10.1186/1471-2407-11-453

Ejemplares similares